Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025
Arvinas:Vepdegestrant將與輝瑞的Cdk4抑制劑Atirmociclib聯合使用,計劃於2025年啓動的第一線3期試驗
Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025
Arvinas:Vepdegestrant將與輝瑞的Cdk4抑制劑Atirmociclib聯合使用,計劃於2025年啓動的第一線3期試驗
使用瀏覽器的分享功能,分享給你的好友吧